Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Checkpoint inhibitors (CPI) have revolutionized the treatment paradigm for advanced solid tumors; however, there remains an opportunity to improve response rates and outcomes. In preclinical models, 4-1BB costimulation synergizes with CPIs targeting the programmed cell death protein 1 (PD-1)/program...

Descripción completa

Detalles Bibliográficos
Autores principales: Muik, Alexander, Garralda, Elena, Altintas, Isil, Gieseke, Friederike, Geva, Ravit, Ben-Ami, Eytan, Maurice-Dror, Corinne, Calvo, Emiliano, LoRusso, Patricia M., Alonso, Guzman, Rodriguez-Ruiz, Maria E., Schoedel, Kristina B., Blum, Jordan M., Sänger, Bianca, Salcedo, Theodora W., Burm, Saskia M., Stanganello, Eliana, Verzijl, Dennis, Vascotto, Fulvia, Sette, Angelica, Quinkhardt, Juliane, Plantinga, Theo S., Toker, Aras, van den Brink, Edward N., Fereshteh, Mark, Diken, Mustafa, Satijn, David, Kreiter, Sebastian, Breij, Esther C.W., Bajaj, Gaurav, Lagkadinou, Eleni, Sasser, Kate, Türeci, Özlem, Forssmann, Ulf, Ahmadi, Tahamtan, Şahin, Uğur, Jure-Kunkel, Maria, Melero, Ignacio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662884/
https://www.ncbi.nlm.nih.gov/pubmed/35176764
http://dx.doi.org/10.1158/2159-8290.CD-21-1345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662884/
https://www.ncbi.nlm.nih.gov/pubmed/35176764
http://dx.doi.org/10.1158/2159-8290.CD-21-1345

Ejemplares similares